Navigation Links
EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
Date:10/22/2007

TARRYTOWN, N.Y., Oct. 22 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Dr. Ben Tseng, Chief Scientific Officer, will present the results of studies examining the combination of EPC2407 with cancer therapeutics in preclinical animal models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA on October 24, 2007. EPC2407 is EpiCept's novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas that recently completed enrollment in a Phase Ia single agent trial.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

The preclinical studies examined the effectiveness of combining EPC2407 with an anti-angiogenesis inhibitor, Avastin(R) or Sutent(R), or with the chemotherapeutic agent cisplatin. EPC2407 was administered in combination with a cancer therapeutic agent in mouse xenograft models of human non-small cell lung carcinomas and human breast carcinomas. These studies indicated significantly enhanced anti-tumor activity when EPC2407 was added to the therapeutic regimen, compared with either agent administered alone, which resulted in increased median survival and number of tumor-free animals well after the end of treatment (>2.5 months). The results demonstrated additive to synergistic activity when EPC2407 is used in combination with these cancer therapeutics.

These results strongly support the clinical testing of EPC2407 in combination with different anti-cancer agents. Advancement of EPC2407 in clinical trials to Phase Ib combination studies is planned to initiate in early 2008.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. EpiCept Accelerates Development of Phase I Clinical Study for Cancer
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group filed ... Paz. , Schmidt National Law Group, a leading firm in mass-tort litigation, has ... Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to have ...
(Date:9/4/2015)... ... 04, 2015 , ... IVF New England, one of the largest and most ... Hour" in Manchester for women who wish to learn more about their fertility and ... and lounge, 827 Elm Street, Manchester, NH from 6PM to 7PM , This hip, ...
(Date:9/4/2015)... ... September 04, 2015 , ... After wearing the same uniforms for ... new apparel. In an effort to assist the team, the Jones Agency, a locally ... drive to raise funds for the new uniforms. , As is so often the ...
(Date:9/4/2015)... ... September 04, 2015 , ... A Union County charitable ... Core Compassion Project is a non-profit organization dedicated to offering Pilates scholarships to ... cancer treatments and recover their mobility, strength, and range of motion following breast ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Keeping mold ... and around the home is quite common. Mold can grow anywhere - on carpet, ... leaking pipes. Checking for excessive moisture and water in the home is key to ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4
... scientists at Bonn University have created a software system that ... //With the aid of the software, the visual prosthesis "learns" ... be interpreted by the brain. ,Nearly two dozens of ... implanted with a visual prosthesis. For this purpose, clinicians open ...
... Hormone Replacement Therapy (HRT), good or bad? //, Till ... menopausal women by giving them measured doses of female hormones, ... such as breast cancer, and heart disease often outweighed its ... mainly due to a 2002 study conducted for the prestigious ...
... to hospital research, almost 50 percent of Kenya’s gynecological ... wrong, often dangerous way. ,The research, ... in western Kenya, also observed that the sufferers were ... study, which appeared in the East African Medical Journal ...
... important lifeline of the growing Indian economy, Hollywood star Richard ... HIV.// ,"Since truck drivers stay out of home ... desires which finally ends up in spreading HIV. I have ... urging them to become responsible," Gere told reporters here Sunday. ...
... results of a new HIV drug has raised the prospect ... which the immune system begins to fail. // ,The ... least 178 patients with advanced HIV who were not responding ... HIV genetic material (RNA) in the blood of the patients ...
... predominantly composed of turmeric root extract and other spices ... a turmeric root extract, has been shown to possess ... sclerosis, and Alzheimer's disease. The molecular mechanism for its ... to inhibit the synthesis of MDM2, an oncoprotein known ...
Cached Medicine News:Health News:Software System to Improve the Function of Retinal Implants 2Health News:Software System to Improve the Function of Retinal Implants 3Health News:Hormone Replacement Therapy – To Choose Or No 2Health News:Improper Abortions- Kenyan Teenagers At Risk 2Health News:Anticancer Effects of Curcumin Revealed 2
(Date:9/4/2015)... Therapeutics, Inc. (Nasdaq: OREX ) today announced that management ... 2015 Healthcare Conference in Boston . The ... 2:30 p.m. Eastern Time. To listen to the live webcast ... section of the Company,s Web site at www.orexigen.com . ... event.  Orexigen Contact: , Media Contact: McDavid ...
(Date:9/4/2015)... 2015  PTC Therapeutics, Inc. (NASDAQ: PTCT ... its first-ever global awards program, the STRIVE Awards ... to aid nonprofit organizations that are committed to ... announcement is made as the global DMD community ... on Monday, September 7, 2015. "We ...
(Date:9/4/2015)... September 4, 2015 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral ... participate in the upcoming Rodman & Renshaw 17 th ... 2015 in New York City . ... present a corporate overview on September 9, 2015. ...
Breaking Medicine Technology:PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... Feb. 23, 2012   Talyst , a leader in ... was founded in 2002 and is dedicated to providing ... inventory control, enhanced workflow efficiency and improved patient safety. ... is committed to developing innovative products. The company partners ...
... 2012  Doctors and other healthcare professionals have grown increasingly concerned ... taking with regard to Fosamax - a widely used osteoporosis ... The FDA has so far resisted adding ... use. Such labels are necessary in light of the dangers ...
Cached Medicine Technology:Victims of Abnormal Bone Fractures Await Action as FDA Lingers on Edge of Tightening Fosamax Regulations 2
...
The Select 3D Arterial cannulae from Medtronic features a tip configuration which diffuses the flow through multiple outlets. This unique tip design provides reduced velocity with one central and thr...
The Medtronic EOPA CAP® arterial cannula provides a simple solution to obtaining accurate arterial pressure readings....
Intermittent catheter...
Medicine Products: